A small molecule inhibitor of NR2F2 was recently shown to reduce prostate cancer tumor growth, specifically by interrupting the interaction of NR2F2 with FOXA1, a master regulator in prostate tumorigenesis.38 This evidence concerns the gene FOXA1 and prostate carcinoma.